• 1
    DeAngelis LM. Current management of primary central nervous system lymphoma. Oncology (Huntingt). 1995; 9: 6371; discussion 71, 75–66, 78.
  • 2
    Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972; 29: 252260.
  • 3
    Levine AM. Non-Hodgkin's lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin Oncol. 1987; 14(2 Suppl 3 ): 3439.
  • 4
    Morgello S, Petito CK, Mouradian JA. Central nervous system lymphoma in the acquired immunodeficiency syndrome. Clin Neuropathol. 1990; 9: 205215.
  • 5
    Levine AM. AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst. 1993; 85: 13821397.
  • 6
    Hobson DE, Anderson BA, Carr I, West M. Primary lymphoma of the central nervous system: Manitoba experience and literature review. Can J Neurol Sci. 1986; 13: 5561.
  • 7
    Ioachim HL, Cooper MC, Hellman GC. Lymphomas in men at high risk for acquired immune deficiency syndrome (AIDS). A study of 21 cases. Cancer. 1985; 56: 28312842.
  • 8
    Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg. 1986; 65: 600607.
  • 9
    Sutcliffe SB, Gospodarowicz MK, Bush RS, et al. Role of radiation therapy in localized non-Hodgkin's lymphoma. Radiother Oncol. 1985; 4: 211223.
  • 10
    Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys. 1992; 23: 917.
  • 11
    Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998; 16: 859863.
  • 12
    McLaughlin P, Velasquez WS, Redman JR, et al. Chemotherapy with dexamethasone, high-dose cytarabine, and cisplatin for parenchymal brain lymphoma. J Natl Cancer Inst. 1988; 80: 14081412.
  • 13
    Sano K, Sato F, Hoshino T, Nagai M. Experimental and clinical studies of radiosensitizers in brain tumors, with special reference to BUdR-antimetabolite continuous regional infusion-radiation therapy. Neurol Med Chir (Tokyo). 1965; 7: 5172.
  • 14
    Sano K, Hoshino T, Nagai M. Radiosensitization of brain tumor cells with a thymidine analogue. J Neurosurg. 1968; 28: 530538.
  • 15
    Hoshino T, Sano K. Radiosensitization of malignant brain tumours with bromouridine. Acta Radiol Ther Phys Biol. 1969; 8: 1526.
  • 16
    Goz B. the effects of incorporation of 5-halogenated deoxyuridines into the DNA of eukaryotic cells. Pharmacol Rev. 1977; 29: 249272.
  • 17
    Schneider DO, Johns RM. Enhancement of radiation-induced mitotic inhibition by BUdR incorporation in L-cells. Radiat Res. 1966; 28: 657667.
  • 18
    Wechsler. Wechsler adult intelligence scale-revised. San Antonio: The psychological Corporation, 1981.
  • 19
    Benedict RB, Schretlen D, Groninger L. Hopkins verbal learning test-revised: normative data and analysis of inter-form and test-retest reliability. Clin Neuropsychol. 1998; 12: 4355.
  • 20
    Sivan AB. Benton Visual Retention Test, 5th edition. San Antonio: The Psychological Corporation, 1992.
  • 21
    Benton AL, Hamsher KdeS. Multilingual aphasia examination. Iowa City: AJA Associates, 1989.
  • 22
    Lezak MD. Neuropsychological assessment, 3rd edition. New York: Oxford University Press, 1995.
  • 23
    Beck AT, Steer RA, Brown GK. Beck depression inventory, 2nd edition. San Antonio: The Psychological Corporation, 1996.
  • 24
    Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press, 1983.
  • 25
    Dixon DO, McLaughlin P, Hagemeister FB, et al. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987; 5: 16701672.
  • 26
    Kaplan EL, Meier P. Non parameteric estimation from incomplete observation. J Am Stat Assoc. 1958; 53: 457481.
  • 27
    Watne K, Scott H, Hager B, et al. Primary malignant lymphoma of the brain. A report of 24 cases from the Norwegian Radium Hospital. Acta Oncol. 1992; 31: 545550.
  • 28
    Socie G, Piprot-Chauffat C, Schlienger M, et al. Primary lymphoma of the central nervous system. An unresolved therapeutic problem. Cancer. 1990; 65: 322326.
  • 29
    Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer. 1989; 63: 939947.
  • 30
    Berry MP, Simpson WJ. Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys. 1981; 7: 5559.
  • 31
    DeAngelis LM, Yahalom J, Rosenblum M, Posner JB. Primary CNS lymphoma: managing patients with spontaneous and AIDS- related disease. Oncology (Huntingt). 1987; 1: 5262.
  • 32
    Fuks Z, Kaplan HS. Recurrence rates following radiation therapy of nodular and diffuse malignant lymphomas. Radiology. 1973; 108: 675684.
  • 33
    Bush RS, Gospodarowicz M, Sturgeon J, Alison R. Radiation therapy of localized non-Hodgkin's lymphoma. Cancer Treat Rep. 1977; 61: 11291136.
  • 34
    Goffman TE, Glatstein E. CNS lymphoma: back to the drawing board. Int J Radiat Oncol Biol Phys. 1992; 23: 247248.
  • 35
    Stewart DJ, Russell N, Atack EA, Quarrington A, Stolbach L. Cyclophosphamide, doxorubicin, vincristine, and dexamethasone in primary lymphoma of the brain: a case report. Cancer Treat Rep. 1983; 67: 287291.
  • 36
    Schultz C, Scott C, Sherman W, et al. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996; 14: 556564.
  • 37
    O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys. 1995; 33: 663673.
  • 38
    Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998; 16: 864871.
  • 39
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993; 328: 10021006.
  • 40
    DeAngelis LM. Primary central nervous system lymphoma. J Neurol Neurosurg Psychiatry. 1999; 66: 699701.
  • 41
    Bleyer WA. Neurologic sequelae of methotrexate and ionizing radiation: a new classification. Cancer Treat Rep. 1981; 65 (Suppl 1): 8998.
  • 42
    Geyer JR, Taylor EM, Milstein JM, et al. Radiation, methotrexate, and white matter necrosis: laboratory evidence for neural radioprotection with preirradiation methotrexate. Int J Radiat Oncol Biol Phys. 1988; 15: 373375.
  • 43
    Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Cancer Res. 1990; 50: 65256528.
  • 44
    Kriss JP, Revesz L. The distribution and fate of bromodeoxyuridine and bromodeoxycytidine. Cancer Res. 1962; 22: 254265.
  • 45
    Kriss JP, Maruyama Y, Tung LA, Bond SB, Revesz L. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine, and 5- iododeoxyuridine. Cancer Res. 1963; 23: 260268.
  • 46
    Kinsella TJ, Russo A, Mitchell JB, et al. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int J Radiat Oncol Biol Phys 1984; 10: 6976.
  • 47
    Phuphanich S, Levin EM, Levin VA. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. Int J Radiat Oncol Biol Phys. 1984; 10: 17691772.